FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2118706017> ?p ?o ?g. }

• W2118706017 endingPage "1713" @default.
• W2118706017 startingPage "1705" @default.
• W2118706017 abstract "Background Ankylosing spondylitis is a chronic immune-mediated inflammatory disease characterised by spinal inflammation, progressive spinal rigidity, and peripheral arthritis. Interleukin 17 (IL-17) is thought to be a key inflammatory cytokine in the development of ankylosing spondylitis, the prototypical form of spondyloarthritis. We assessed the efficacy and safety of the anti-IL-17A monoclonal antibody secukinumab in treating patients with active ankylosing spondylitis. Methods We did a randomised double-blind proof-of-concept study at eight centres in Europe (four in Germany, two in the Netherlands, and two in the UK). Patients aged 18–65 years were randomly assigned (in a 4:1 ratio) to either intravenous secukinumab (2×10 mg/kg) or placebo, given 3 weeks apart. Randomisation was done with a computer-generated block randomisation list without a stratification process. The primary efficacy endpoint was the percentage of patients with a 20% response according to the Assessment of SpondyloArthritis international Society criteria for improvement (ASAS20) at week 6 (Bayesian analysis). Safety was assessed up to week 28. This study is registered with ClinicalTrials.gov, number NCT00809159. Findings 37 patients with moderate-to-severe ankylosing spondylitis were screened, and 30 were randomly assigned to receive either intravenous secukinumab (n=24) or placebo (n=6). The final efficacy analysis included 23 patients receiving secukinumab and six patients receiving placebo, and the safety analysis included all 30 patients. At week 6, ASAS20 response estimates were 59% on secukinumab versus 24% on placebo (99·8% probability that secukinumab is superior to placebo). One serious adverse event (subcutaneous abscess caused by Staphylococcus aureus) occurred in the secukinumab-treated group. Interpretation Secukinumab rapidly reduced clinical or biological signs of active ankylosing spondylitis and was well tolerated. It is the first targeted therapy that we know of that is an alternative to tumour necrosis factor inhibition to reach its primary endpoint in a phase 2 trial. Funding Novartis." @default.
• W2118706017 created "2016-06-24" @default.
• W2118706017 creator A5000282057 @default.
• W2118706017 creator A5000823009 @default.
• W2118706017 creator A5009083245 @default.
• W2118706017 creator A5011323027 @default.
• W2118706017 creator A5015732937 @default.
• W2118706017 creator A5021492067 @default.
• W2118706017 creator A5026797171 @default.
• W2118706017 creator A5031269142 @default.
• W2118706017 creator A5032987311 @default.
• W2118706017 creator A5035639364 @default.
• W2118706017 creator A5044386973 @default.
• W2118706017 creator A5046625022 @default.
• W2118706017 creator A5048528703 @default.
• W2118706017 creator A5054905775 @default.
• W2118706017 creator A5057713351 @default.
• W2118706017 creator A5064220409 @default.
• W2118706017 creator A5069831361 @default.
• W2118706017 creator A5070567555 @default.
• W2118706017 creator A5075106239 @default.
• W2118706017 creator A5080456360 @default.
• W2118706017 creator A5085745432 @default.
• W2118706017 creator A5089158758 @default.
• W2118706017 creator A5091263515 @default.
• W2118706017 date "2013-11-01" @default.
• W2118706017 modified "2023-10-17" @default.
• W2118706017 title "Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial" @default.
• W2118706017 cites W1508752722 @default.
• W2118706017 cites W1878264508 @default.
• W2118706017 cites W1964156630 @default.
• W2118706017 cites W1964722637 @default.
• W2118706017 cites W1966756689 @default.
• W2118706017 cites W1976173775 @default.
• W2118706017 cites W1981924088 @default.
• W2118706017 cites W1984626603 @default.
• W2118706017 cites W1989969667 @default.
• W2118706017 cites W1991099151 @default.
• W2118706017 cites W1997764596 @default.
• W2118706017 cites W2006154561 @default.
• W2118706017 cites W2010622913 @default.
• W2118706017 cites W2026258433 @default.
• W2118706017 cites W2030187620 @default.
• W2118706017 cites W2038377490 @default.
• W2118706017 cites W2046579578 @default.
• W2118706017 cites W2048020246 @default.
• W2118706017 cites W2071343804 @default.
• W2118706017 cites W2071582474 @default.
• W2118706017 cites W2097896494 @default.
• W2118706017 cites W2102994864 @default.
• W2118706017 cites W2112128505 @default.
• W2118706017 cites W2118434625 @default.
• W2118706017 cites W2126477323 @default.
• W2118706017 cites W2127834887 @default.
• W2118706017 cites W2132784721 @default.
• W2118706017 cites W2156459362 @default.
• W2118706017 cites W2159788225 @default.
• W2118706017 cites W2164617201 @default.
• W2118706017 cites W2322390243 @default.
• W2118706017 cites W2330168404 @default.
• W2118706017 cites W4211170289 @default.
• W2118706017 cites W4250753642 @default.
• W2118706017 doi "https://doi.org/10.1016/s0140-6736(13)61134-4" @default.
• W2118706017 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24035250" @default.
• W2118706017 hasPublicationYear "2013" @default.
• W2118706017 type Work @default.
• W2118706017 sameAs 2118706017 @default.
• W2118706017 citedByCount "496" @default.
• W2118706017 countsByYear W21187060172013 @default.
• W2118706017 countsByYear W21187060172014 @default.
• W2118706017 countsByYear W21187060172015 @default.
• W2118706017 countsByYear W21187060172016 @default.
• W2118706017 countsByYear W21187060172017 @default.
• W2118706017 countsByYear W21187060172018 @default.
• W2118706017 countsByYear W21187060172019 @default.
• W2118706017 countsByYear W21187060172020 @default.
• W2118706017 countsByYear W21187060172021 @default.
• W2118706017 countsByYear W21187060172022 @default.
• W2118706017 countsByYear W21187060172023 @default.
• W2118706017 crossrefType "journal-article" @default.
• W2118706017 hasAuthorship W2118706017A5000282057 @default.
• W2118706017 hasAuthorship W2118706017A5000823009 @default.
• W2118706017 hasAuthorship W2118706017A5009083245 @default.
• W2118706017 hasAuthorship W2118706017A5011323027 @default.
• W2118706017 hasAuthorship W2118706017A5015732937 @default.
• W2118706017 hasAuthorship W2118706017A5021492067 @default.
• W2118706017 hasAuthorship W2118706017A5026797171 @default.
• W2118706017 hasAuthorship W2118706017A5031269142 @default.
• W2118706017 hasAuthorship W2118706017A5032987311 @default.
• W2118706017 hasAuthorship W2118706017A5035639364 @default.
• W2118706017 hasAuthorship W2118706017A5044386973 @default.
• W2118706017 hasAuthorship W2118706017A5046625022 @default.
• W2118706017 hasAuthorship W2118706017A5048528703 @default.
• W2118706017 hasAuthorship W2118706017A5054905775 @default.
• W2118706017 hasAuthorship W2118706017A5057713351 @default.
• W2118706017 hasAuthorship W2118706017A5064220409 @default.
• W2118706017 hasAuthorship W2118706017A5069831361 @default.
• W2118706017 hasAuthorship W2118706017A5070567555 @default.

• next